

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津发展控股有限公司
TIANJIN DEVELOPMENT HOLDINGS LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 882)

**UNAUDITED FINANCIAL RESULTS
FOR THE SIX MONTHS ENDED 30 JUNE 2021
OF TIANJIN LISHENG PHARMACEUTICAL CO., LTD.**

This announcement is made by Tianjin Development Holdings Limited (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited to provide shareholders of the Company and the public with the unaudited consolidated financial results of its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生製藥股份有限公司) (“**Lisheng Pharmaceutical**”), for the six months ended 30 June 2021.

Lisheng Pharmaceutical is a company incorporated in the People’s Republic of China whose shares are listed on the Shenzhen Stock Exchange. As at the date of this announcement, the Company indirectly holds approximately 34.41% of the issued share capital of Lisheng Pharmaceutical. The unaudited consolidated income statement for the six months ended 30 June 2021 and the unaudited condensed consolidated balance sheet as at 30 June 2021 of Lisheng Pharmaceutical prepared in accordance with China Accounting Standards for Business Enterprises are provided below:

Tianjin Lisheng Pharmaceutical Co., Ltd.
Consolidated Income Statement
For the six months ended 30 June 2021

	For the six months ended 30 June	
	2021	2020
	RMB	RMB
	(unaudited)	(unaudited)
1. Total operating income	587,330,610.63	613,859,637.68
Including: Operating income	587,330,610.63	613,859,637.68
2. Total operating costs	523,754,645.50	558,793,606.43
Including: Costs of sales	245,086,722.89	221,321,592.57
Business tax and surcharge	11,150,915.96	12,231,321.89
Selling expenses	183,174,938.76	248,229,282.71
Administrative expenses	51,207,428.86	51,843,323.13
Research expenses	59,222,366.83	39,929,137.89
Finance expenses	-26,087,727.80	-14,761,051.76
Including: Interest expenses	137,308.02	609,100.09
Interest income	26,325,845.70	15,319,596.28
Add: Other gains	3,057,568.48	4,529,222.48
Investment income	7,788,146.51	7,649,605.49
Including: Investment income from associates and joint ventures	7,788,146.51	6,524,605.49
Incomes from change in fair value	700,770.00	—
Impairment losses on credit	45,394.85	-13,562.04
3. Operating profit	75,167,844.97	67,231,297.18
Add: Non-operating income	220,366.14	961,997.88
Less: Non-operating expenses	215,185.27	172,650.01
4. Total profit	75,173,025.84	68,020,645.05
Less: Income tax expenses	13,920,237.21	11,453,612.19
5. Net profit	61,252,788.63	56,567,032.86
Net profit attributable to owners of parent company	61,252,788.63	56,567,032.86
6. Other comprehensive income, net of tax	—	—
7. Total comprehensive income	61,252,788.63	56,567,032.86
Total comprehensive income attributable to owners of parent company	61,252,788.63	56,567,032.86
8. Earnings per share:		
(1) Basic earnings per share (RMB/share)	0.34	0.31
(2) Diluted earnings per share (RMB/share)	0.34	0.31

Tianjin Lisheng Pharmaceutical Co., Ltd.
Condensed Consolidated Balance Sheet
As at 30 June 2021

	At 30 June 2021 RMB (unaudited)	At 31 December 2020 RMB (audited)
ASSETS		
Current assets	2,297,605,459.50	2,244,370,080.04
Non-current assets	<u>2,794,052,307.30</u>	<u>2,777,812,908.95</u>
Total assets	<u><u>5,091,657,766.80</u></u>	<u><u>5,022,182,988.99</u></u>
LIABILITIES		
Current liabilities	524,390,407.47	502,759,834.78
Non-current liabilities	<u>223,070,725.07</u>	<u>217,327,396.52</u>
Total liabilities	<u><u>747,461,132.54</u></u>	<u><u>720,087,231.30</u></u>
OWNERS' EQUITY		
Share capital	182,454,992.00	182,454,992.00
Capital reserves	1,691,564,108.23	1,691,564,108.23
Other comprehensive income	1,005,189,102.53	1,005,189,102.53
Special reserves	13,869,406.29	14,775,819.15
Surplus reserves	402,847,934.45	402,847,934.45
Undistributed profit	<u>1,048,271,090.76</u>	<u>1,005,263,801.33</u>
Total equity attributable to owners of parent company	<u><u>4,344,196,634.26</u></u>	<u><u>4,302,095,757.69</u></u>
TOTAL OWNERS' EQUITY	<u><u>4,344,196,634.26</u></u>	<u><u>4,302,095,757.69</u></u>
TOTAL LIABILITIES AND OWNERS' EQUITY	<u><u>5,091,657,766.80</u></u>	<u><u>5,022,182,988.99</u></u>

Shareholders of the Company should note that the above unaudited financial information pertains only to Lisheng Pharmaceutical and not to the Company itself.

Details of the unaudited consolidated financial results of Lisheng Pharmaceutical for the six months ended 30 June 2021 are available on the website of Shenzhen Stock Exchange (www.szse.cn).

By Order of the Board
Tianjin Development Holdings Limited
Chen Yanhua
Executive Director and General Manager

Hong Kong, 24 August 2021

As at the date of this announcement, the board of directors of the Company consists of Mr. Zhang Bingjun, Mr. Chen Yanhua, Dr. Li Xiaoguang, Mr. Zhuang Qifei, Mr. Cui Xiaofei, Mr. Cheung Wing Yui, Edward, Dr. Cheng Hon Kwan**, Mr. Mak Kwai Wing, Alexander**, Ms. Ng Yi Kum, Estella**, Mr. Wong Shiu Hoi, Peter** and Dr. Loke Yu**.*

* *non-executive director*

** *independent non-executive director*